INVESTORS / INVESTMENT OPPORTUNITIES
Cancer immunotherapy drugs are by far the fastest-growing segment of the oncology drug industry.
multimmune GmbH's cancer theranostics programmes have been supported by investment from a number of sources:
- Technology Investment Fund Bayern III GmbH & Co. KG / Bayern Kapital GmbH
- S-Refit AG / Sobera Capital GmbH
- RAABE Asset Management GmbH
- SilverSky LifeSciences GmbH
- Private investors
- Non-dilutive funding from a variety of funding agencies